Clinically and orally compatible formulation-manufactured DDX5 (p68)-targeting molecular glue FL118 products exhibit low toxicity but high efficacy against human cancer

J Pharm Anal. 2024 Nov;14(11):101001. doi: 10.1016/j.jpha.2024.101001. Epub 2024 May 13.

Xiang Ling^{1

2}, Wenjie Wu^{1

2}, Li Yan³, Leslie Curtin⁴, Melanie M Farrauto⁴, Sandra Sexton⁴, Anmbreen Jamroze¹, Changjun Yu⁵, Christos Fountzilas^{6

7

8}, Dean G Tang^{1

7

9}, Fengzhi Li^{1

7

8

9}

¹ Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA.
² Canget BioTekpharma LLC, Buffalo, New York, 14203, USA.
³ Department of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center Buffalo, New York, 14263, USA.
⁴ Comparative Oncology Shared Resources, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA.
⁵ California Institute of Technology, Pasadena, CA, 91125, USA.
⁶ Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA.
⁷ Developmental Therapeutics (DT) Program, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA.
⁸ Pancreatic Cancer Research Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA.
⁹ Genitourinary (GU) Oncology Research Center, Roswell Park Comprehensive Cancer Center, Buffalo, New York, 14263, USA.

Abstract

Image 1.